Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeting Inflammation and Alloimmunity in Lung Transplant Recipients With Tocilizumab
NCT06033196Phase 2Recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Feb 2024
- Primary completion
- Jan 2029
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tocilizumab in lung transplant rejection, sponsored by National Institute of Allergy and Infectious Diseases. Started Feb 2024; status: recruiting.
02
Drugs
tocilizumab
03
Conditions
lung transplant rejection
Beyond the preview
Go deeper on NCT06033196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06033196.